Dr. Ooi is an Al and Val Rosentrauss Fellow at Monash University. He specializes in the identification of autoimmune T cell epitopes and understanding the basis of autoimmune susceptibilities. He has shown that the frequencies of antigen specific regulatory T cells are a key determinant for protection from autoimmune disease. Alongside mentor Prof. Richard Kitching, Dr. Ooi received his first NHMRC Project Grant in 2018 to develop therapeutic strategies using antigen specific regulatory T cells.
Barbara Murphy, MB, BAO, BCh, FRCPI, is the Chair of the Samuel Bronfman Department of Medicine, the Murray M. Rosenberg Professor of Medicine, and the Dean of Clinical Integration and Population Management at the Icahn School of Medicine at the Mount Sinai Health System. Dr. Murphy earned her medical degree from The Royal College of Surgeons in Ireland. She did her clinical training in internal medicine and fellowship in clinical nephrology at Beaumont Hospital, Dublin and completed her postdoctoral training in nephrology and transplant immunology at Brigham and Women’s Hospital, Harvard Medical School. She was recruited to Mount Sinai as Director of Transplant Nephrology, where she was subsequently named Chief of the Division of Nephrology in and then Chair of Medicine in 2012. At a national level Dr. Murphy has held many leadership positions in the American Society of Transplantation and American Society of Nephrology including being a past President of the American Society of Transplantation and most recently she was elected to ASN council.
Dr Murphy’s research focuses on the use of high throughput genomic technologies as a means to understand the immune mechanisms that lead to graft injury and loss, with the aim of identifying gene expression profiles and genetic variants that may be used to predict outcomes post transplantation. Work lead by Dr Murphy, as part of a large collaborative study (GoCAR), has identified a peripheral expression gene profile that diagnoses subclinical acute rejection and stratifies patients based on immunological risk, and demonstrated that expression within the graft early post transplant identifies patients at greatest risk for fibrosis and graft loss